IMMX insider filings
Immix Biopharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-20. Screen IMMX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings by 2 insiders — 2,826 shares, $20,011 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 1,418 shares @ $7.06 ($10,011) by Morris Gabriel S, filed 2026-11-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Morris Gabriel S — CFO, President, Director | 1 | 1 leg · 1,418 sh · $10,011 | — | — |
| Rachman Ilya M — CEO, Chairman, Director | 1 | 1 leg · 1,408 sh · $10,000 | — | — |
Recent insider filings — Immix Biopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-20 | 4 | Morris Gabriel S — CFO, President, Director | Purchase (P): 1,418 @ $7.06 | EDGAR |
| 2026-11-20 | 4 | Rachman Ilya M — CEO, Chairman, Director | Purchase (P): 1,408.45 @ $7.10 | EDGAR |
| 2026-05-29 | 4 | Ng Carey — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Morris Gabriel S — CFO, President, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Rachman Ilya M — CEO and Chairman, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Chudnovsky Yekaterina — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Hsu Jason — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Marquet Magda — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Adams Helen C. — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | BUCHAN JANE — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | CHANG NANCY T — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | CHANG NANCY T — Director | Grant/award (A): 39,643 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Rachman Ilya M — CEO and Chairman, Director | Purchase (P): 746 @ $6.67 | EDGAR |
| 2025-12-10 | 4 | Morris Gabriel S — CFO, Director | Option exercise/expiry (X): 156,000 @ $0.80 · Purchase (P): 770 @ $6.58 · Option exercise/expiry (X): 96,000 (derivative) @ $0 · Option exercise/expiry (X): 60,000 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Rachman Ilya M — CEO and Chairman, Director | Purchase (P): 2,500 @ $2.02 | EDGAR |
| 2025-09-17 | 4 | Morris Gabriel S — CFO, Director | Purchase (P): 2,600 @ $1.97 | EDGAR |
| 2025-06-23 | 4 | Rachman Ilya M — CEO and Chairman, Director | Grant/award (A): 340,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Ng Carey — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Morris Gabriel S — CFO, Director | Grant/award (A): 340,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Hsu Jason — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Chudnovsky Yekaterina — Director, 10% owner | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Marquet Magda — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Adams Helen C. — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | BUCHAN JANE — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Rachman Ilya M — CEO and Chairman, Director | Purchase (P): 2,178 @ $2.29 | EDGAR |
| 2025-06-20 | 4 | Morris Gabriel S — CFO, Director | Purchase (P): 2,225 @ $2.28 | EDGAR |
| 2024-12-26 | 4 | Hsu Jason — Director | Purchase (P): 7,700 @ $2.17 · Purchase (P): 40,000 @ $2.19 | EDGAR |
| 2024-08-26 | 4 | Hsu Jason — Director | Purchase (P): 15,000 @ $2.23 · Purchase (P): 8,100 @ $2.25 | EDGAR |
| 2024-08-19 | 4 | Ng Carey — Director | Purchase (P): 10,000 @ $1.86 | EDGAR |
| 2024-07-31 | 4 | Hsu Jason — Director | Purchase (P): 3,200 @ $2.07 · Purchase (P): 6,000 @ $2.15 | EDGAR |
| 2024-06-21 | 4 | Rachman Ilya M — CEO and Chairman, Director | Grant/award (A): 340,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Ng Carey — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Morris Gabriel S — CFO, Director | Grant/award (A): 340,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Hsu Jason — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Chudnovsky Yekaterina — Director, 10% owner | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Marquet Magda — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Adams Helen C. — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | BUCHAN JANE — Director | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Morris Gabriel S — CFO, Director | Purchase (P): 2,500 @ $2.12 | EDGAR |
| 2024-06-10 | 4 | Rachman Ilya M — CEO and Chairman, Director | Purchase (P): 2,600 @ $2.13 | EDGAR |
| 2024-06-05 | 4 | Morris Gabriel S — CFO, Director | Purchase (P): 3,300 @ $1.81 | EDGAR |
| 2024-06-05 | 4 | Rachman Ilya M — CEO and Chairman, Director | Purchase (P): 3,300 @ $1.81 | EDGAR |
| 2024-05-20 | 4 | Hsu Jason — Director | Grant/award (A): 21,587 (derivative) @ $0 · Grant/award (A): 25,512 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Rachman Ilya M — CEO and Chairman, Director | Grant/award (A): 218,359 | EDGAR |
| 2024-05-20 | 4 | Morris Gabriel S — CFO, Director | Grant/award (A): 194,218 · Grant/award (A): 24,141 · Grant/award (A): 24,141 | EDGAR |
| 2024-05-20 | 4 | Ng Carey — Director | Grant/award (A): 21,587 (derivative) @ $0 · Grant/award (A): 25,512 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Marquet Magda — Director | Grant/award (A): 25,002 @ $0 · Grant/award (A): 21,155 | EDGAR |
| 2024-05-20 | 4 | Adams Helen C. — Director | Grant/award (A): 87,740 @ $0 · Grant/award (A): 74,241 | EDGAR |
| 2024-05-20 | 4 | BUCHAN JANE — Director | Grant/award (A): 1,332 @ $0 · Grant/award (A): 1,127 · Grant/award (A): 20,436 (derivative) @ $0 · Grant/award (A): 24,153 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Rachman Ilya M — CEO and Chairman, Director | Purchase (P): 4,300 @ $2.25 | EDGAR |
Recent 8-K events — Immix Biopharma, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IMMX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs